Posted by on Aug 26, 2017 in Diabetes mellitus | 0 comments

In a nutshell

This study assessed the safety and effectiveness of a new formulation of exenatide compared to sitaglipitin in patients with sub-optimal blood sugar control taking metformin.

This study concluded that exenatide reduced blood sugar levels over 3 months more effectively than sitaglipitin

Some background

There are many blood glucose-lowering medications available for the treatment of diabetes. Metformin is the first-line treatment for type 2 diabetes. It is often prescribed in combination with other glucose-lowering medications. One type of medication targets a receptor called glucagon-like peptide receptor or GLP-1r. Exenatide and sitagliptin are two such medications. Exenatide activates GLP-1r and sitagliptin enhances activity of GLP-1r.

Exenatide has been shown to be more effective than sitagliptin at reducing blood sugar when administered once weekly using a dual-chamber pen. Exenatide is now available in a suspension form, at the same dose, which makes it easier to administer. Ease of use is important and can impact how well the patient manages blood glucose. 

Methods & findings

The safety and effectiveness of the new formulation of exenatide is investigated in this study.

311 patients with type 2 diabetes were included in this study. Patients were randomly assigned to receive either exenatide once-weekly suspension for autoinjection (QWS-AI), sitagliptin, or placebo (substance with no active effect) while maintaining standard metformin therapy. Assessment was performed at the end of a 28-week period.

Exenatide QWS-AI reduced HbA1c levels (average blood glucose over 3 months) more than sitagliptin or placebo. More patients receiving exenatide QWS-AI achieved an HbA1c level less than 7% (43.1% exenatide versus 32% sitagliptin). 

Body weight decreased with both exenatide QWS-AI and sitagliptin. Side effects were reported by 55.8% of patients receiving exenatide QWS-AI, compared to 32.8% of sitagliptin and 47.5% of placebo patients. The most common side effects associated with exenatide QWS-AI were gastrointestinal (nausea, diarrhea, vomiting) and injection-site reactions.

The bottom line

This study concluded that exenatide QWS-AI is more effective than sitagliptin in reducing blood sugar levels in combination with standard metformin therapy.

What’s next?

Managing blood glucose levels is important for managing type 2 diabetes. Please discuss this with your doctor if you have any concerns.

Published By :

Diabetes, Obesity and Metabolism

Date :

Feb 16, 2017

Original Title :

Efficacy and safety of autoinjected exenatide once-weekly suspension versus sitagliptin or placebo with metformin in patients with type 2 diabetes: the DURATION-NEO-2 randomized clinical study.

click here to get personalized updates